Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06487000 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Determine the Dose-dependent Efficacy and Safety of EC-18 in Patients With Moderate to Severe Atopic Dermatitis

Name: Determine the Dose-dependent Efficacy and Safety of EC-18 in Patients With Moderate to Severe Atopic Dermatitis — clinical trial record (NCT06487000)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 2

SponsorEnzychem Lifesciences Corporation

Started2027-05

View on ClinicalTrials.gov ↗

To evaluate the efficacy and safety of oral administration of dose-dependent EC-18 for 16 weeks in patients with moderate to severe atopic dermatitis

Amendment history 2 changes detected by DataLookout

2026-08-29

Primary completion pushed: 2026-10 → 2027-10

2026-08-29

Completion pushed: 2026-12 → 2027-12

Trial Details

NCT Number	NCT06487000
Lead Sponsor	Enzychem Lifesciences Corporation
Conditions	Atopic Dermatitis
Enrollment	150 participants
Start Date	2027-05
Primary Completion	2027-10 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-08-28